Molecular Templates, Inc. (MTEM): Price and Financial Metrics
MTEM Price/Volume Stats
| Current price | $1.45 | 52-week high | $9.45 |
| Prev. close | $1.49 | 52-week low | $1.41 |
| Day low | $1.41 | Volume | 9,406 |
| Day high | $1.46 | Avg. volume | 53,553 |
| 50-day MA | $2.77 | Dividend yield | N/A |
| 200-day MA | $5.26 | Market Cap | 7.79M |
MTEM Stock Price Chart Interactive Chart >
Molecular Templates, Inc. (MTEM) Company Bio
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is based in Austin, Texas.
Latest MTEM News From Around the Web
Below are the latest news stories about MOLECULAR TEMPLATES INC that investors may wish to consider to help them evaluate MTEM as an investment opportunity.
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business UpdateMT-6402 Dose Escalation (Part A) Head & Neck Patients (N=8) AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results and business updates for the th |
Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid TumorsAUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating MT-8421, a novel engineered toxin body targeting CTLA-4, for the treatment of advanced solid tumors. The Phase 1 study is a multi-center open-lab |
Molecular Templates to Participate in Upcoming Investor ConferencesAUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, today announced participation in the following upcoming investor conferences: UBS Biopharma Conference 2023 Format: One-on-One |
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical OfficerAUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appointment of Dr. Maurizio Voi to the role of Chief Medical Officer. Dr. Voi possesses more than 35 years of wide-ranging drug development experience. Dr. Voi will begin his new role on October 2, 2023. Dr. Voi joins M |
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Molecular Templates Inc. (MTEM)Molecular Templates Inc. (MTEM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen. |
MTEM Price Returns
| 1-mo | -17.61% |
| 3-mo | -61.07% |
| 6-mo | -76.61% |
| 1-year | -78.33% |
| 3-year | -98.79% |
| 5-year | -98.46% |
| YTD | -61.13% |
| 2023 | -24.19% |
| 2022 | -91.63% |
| 2021 | -58.25% |
| 2020 | -32.86% |
| 2019 | 246.16% |
Continue Researching MTEM
Want to see what other sources are saying about Molecular Templates Inc's financials and stock price? Try the links below:Molecular Templates Inc (MTEM) Stock Price | Nasdaq
Molecular Templates Inc (MTEM) Stock Quote, History and News - Yahoo Finance
Molecular Templates Inc (MTEM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...